Auxiliary partial orthotopic liver transplantation for XXXX : the Hannover experience.

@entity1 @entity879 @entity2102 @entity409 @entity1578 @entity715 @entity1443
APOLT has been developed both to enable the native liver to regenerate in @entity879 and to avoid the risks of long-term immunosuppressive therapy. We present our experience with APOLT in 4 @entity1 with @entity879 . The @entity1 were 33, 18, 5, and 34 years of age, respectively. The causes of @entity1578 were: one @entity2102 , one @entity1443 intoxication, and 2 causes which remained undetermined. All @entity1 were in coma before transplantation. First symptoms had occurred 13, 2, 30, and 20 days prior to APOLT, respectively. In all cases, segments II and III of the recipient's own liver were resected before implanting the @entity409 . The auxiliary graft consisted of segments II and III in 2 cases and of II, III, and IV in the other 2 @entity1 . The auxiliary graft showed good initial function in all cases. All 4 @entity1 are alive 5 years, 15 months, 6 months, and one month after transplantation. In the last @entity1 , an arterial @entity715 of the graft on the 5th postoperative day required retransplantation. The immunosuppressive therapy could be stopped in 3 cases and the graft was removed in 2 @entity1 15 and 40 days after APOLT, respectively. This shows that APOLT represents an effective treatment for @entity1 with @entity879 , which enables restoration of native liver function. Thus, APOLT should be considered in every @entity1 with acute and potentially reversible @entity1578 in whom a transplantation is indicated.
